ArriVent BioPharma, Inc. (AVBP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, ArriVent BioPharma reported revenue of $0. Net income was -$166.3M, or -$4.32 per diluted share. Operating activities generated -$160.6M of cash. At fiscal year end, ArriVent BioPharma held $333.2M in total assets against $25.9M in total liabilities, including $45.5M of cash and equivalents.
Open the full interactive ArriVent BioPharma financials → Quarterly statements, key ratios, valuation history and price charts.
ArriVent BioPharma Key Stats
| Share Price | $16.09 |
|---|---|
| Market Cap | $766.0M |
| 52-Week Range | $15.09 – $34.74 |
| Shares Outstanding | 47.6 million (basic, 2026 Q2) |
ArriVent BioPharma Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$94.3M | -$177.5M |
| Pre-Tax Income | -$80.5M | -$166.3M |
| Net Income | -$80.5M | -$166.3M |
| Diluted EPS | -$2.56 | -$4.32 |
ArriVent BioPharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$35.0M | -$35.5M | -$43.3M | -$49.9M |
| Diluted EPS | -$0.83 | -$0.92 | -$0.96 | -$1.05 |
ArriVent BioPharma Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $74.3M | $45.5M |
| Current Assets | $227.0M | $332.9M |
| Total Assets | $274.9M | $333.2M |
| Current Liabilities | $17.3M | $25.9M |
| Total Liabilities | $17.3M | $25.9M |
| Shareholders' Equity | $257.7M | $307.2M |
ArriVent BioPharma Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$70.2M | -$160.6M |
| Cash From Investing | -$192.5M | -$71.2M |
| Cash From Financing | $186.6M | $203.1M |
Figures from ArriVent BioPharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full ArriVent BioPharma financials page for every line item.
ArriVent BioPharma Company Profile
| Ticker | AVBP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Newtown Square, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001868279 |
Frequently Asked Questions
What was ArriVent BioPharma's revenue in fiscal 2025?
ArriVent BioPharma (AVBP) reported revenue of $0 for fiscal 2025.
What was ArriVent BioPharma's net income in fiscal 2025?
ArriVent BioPharma reported net income of -$166.3M for fiscal 2025.
What was ArriVent BioPharma's earnings per share (EPS) in fiscal 2025?
ArriVent BioPharma's diluted EPS was -$4.32 for fiscal 2025 (adjusted for any later stock splits).
What was ArriVent BioPharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), ArriVent BioPharma reported revenue of $0.
How many shares of ArriVent BioPharma are outstanding?
ArriVent BioPharma reported a weighted average of 47.6 million basic shares outstanding in 2026 Q2.
What is ArriVent BioPharma's market cap?
Based on its latest closing price, ArriVent BioPharma (AVBP) has a market capitalization of about $766.0M.
When does ArriVent BioPharma's fiscal year end?
ArriVent BioPharma's fiscal year end, as registered with the SEC, is December 31.
Where is ArriVent BioPharma headquartered?
ArriVent BioPharma lists its business address in Newtown Square, Pennsylvania in its SEC filings.